Quality by Design


Sushila D. Chavan1*, Nayana V. Pimpodkar2, Amruta S. Kadam1, Puja S.Gaikwad1

1Lecturer, College of Pharmacy (D. Pharm) Degaon, Satara  (MH) India- 415 004.

2Principal, College of Pharmacy (D. Pharm) Degaon, Satara  (MH) India- 415 004.

*Corresponding Author E-mail: sushiladchavan@gmail.com




Quality by design (QbD) is an essential part of the modern advance to pharmaceutical quality. QbD is best key to build a quality in all pharmaceutical products. Under this concepts of Be throughout design and growth of product, it is important to identify desire product performance report [Target product profile (TPP), Quality Target product profile (QTPP)] and identify critical quality attributes (CQA). To recognize the impact of raw material [critical material attributes (CAM)], critical process parameters (CPP) on the CQAs and identification and control sources of changeability. The plan of pharmaceutical development is to design a quality products and its manufacturing process always deliver the future performance of the product. The base of Quality by design is ICH Guidelines Q8 for Pharmaceutical for development, Q9 quality risk management, Q10 for pharmaceutical quality systems.


KEYWORDS: QBD- Quality by Design.






In Quality by Design, Quality is important word. So Quality is “standard or suitability for intended use.” This term includes such attributes as the identity, potency, and purity.


Quality by Design2,11:

Pharmaceutical industry are alert on product Quality,Safety, and Efficacy. Product quality has been increasing by implement scientific tools such as QbD (Quality by Design). Scientific approaches will provide the clear and sufficient knowledge from product development to manufacturing. These QbD tools will minimize the risk by increasing the output and quality.



Nowadays QbD approach has been successfully implemented in common formulation development. USFDA has released specific QbD guidance for immediate and extended release drug products as well as biotechnological products. Regulatory authorities are always proposing the implementation of ICH quality guidelines Q8 to Q11.


According to ICH Q8 guidelines, QbD is defined as, “ A systematic approach to development that begins with predefined objectives and emphasizes product, process understanding and process control, based on sound science and quality risk management.” It means that, design and develop the formulation and manufacturing process to make sure predefined product quality. It requires an understanding of how product and process variables influence product quality. It is a systematic process to build the quality in to final product. QbD requires identification of all critical quality attributes and process parameters as well as determining the level to which any variation can impact the quality of the final product.


Concepts and Background of QbD5-8

Quality by Design is a concept first outlined by Joseph M. Juran in various publications. He supposed that quality could be planned. The concept of QbD was mention in ICH Q8 guidelines, which states that, “To identify quality cannot be tested in products, i.e.  Quality should be built in to product by design.”  In 1970- Toyota pioneered many QbD concepts to improve their early automobiles, since that time other industry technology, telecommunication and aeronautics taken this concept and make QbD. In 1990- Medical devices began to show that incorporated many qualities by design aspects. In mid-2002 FDA published a concept paper on cGMP for 21st century. These documents expressed a desired that companies build quality, safety, and efficacy in to their new product as early as possible.



·         The main objectives of QbD is to ensure the quality products, for that product and process characteristics important to desired performance must be resulting from a combination of prior knowledge and new estimation during development.

·         From this knowledge and data process measurement and desired attributes may be constructed.

·         Experimental study would be viewed as positive performance testing of the model ability through Design space.

·         Ensures combination of product and process knowledge gained during development.




·         Better understanding of the process. 

·         Less Batch failure.

·          Ensure better design of products with less problems in manufacturing.

·          Allows for continuous improvement in products and manufacturing process.



·         Enhances scientific base for analysis.

·         Provide better consistency.

·         Provide for more flexibility in decision making.

·         Ensures decisions made on science and not on observed information.



Traditional Vs. QbD Approach9:

Advancement in the pharmaceutical development and manufacturing by QbD can be explained against traditional approach as below,


Table No.1: Pharmaceutical Asepects: Traditional Vs. QbD Approach




Pharmaceutical Development


Systematic, multivariate experiments.

Mfg. process


Adjustable within design space.

Process control

Offline analysis wide or slow response.

PAT utilized for feedback and provide to real time.

Product Specification

Based on batch data.

Based on the desired product performance.

Control strategy

Mainly by intermediate product and end product testing.

Risk based, Controlled shifted upstream, real time release.

Lifecycle management

Post approval changes needed.

Continual improvement enable with in design space.



Define Target product profile and quality target profile

Identify critical quality attributes

Carry out risk assessment linking material attributes and process parameter to CQAs

Establish design space

Describe control strategy

Life cycle management and continuous improvement

Fig 1. Flow of Quality by Design:



This flow chart gives idea about various steps that involve in Quality by Design development process as below,

1. In QbD Process, first define Target Product profile (TPP) and Quality Target Product Profile (QTPP) which describes use, safety and efficacy of product.

2. Once TPP and QTPP have been identified, the next step is to identify the Critical Quality Attributes. (CQAs)

3. Carry out the risk assessment linking material attributes and process parameters that must be controlled to achieve desired quality product.

4. After that, confirm the Design space (i.e. Requirement for in- process drug substance and drug product attributes) these conditions are established based on several sources of information.

5. Implement a control strategy for the entire process using in – process and end of process controls.

6. Perform the continuous improvement to get consistency in quality of products.



Under this title target is important word. Target is nothing but a result that we try to achieve. So, in this we target the drug profile or target product which ensures desired quality, safety and efficacy. .TPP is defined as, “A prospective summary of the quality characteristics of drug product that ideally will be achieved to ensure the desired quality, taking in to account safety and efficacy of drug product.”(ICH Q8)

Target product profile should includes,

·         Dosage form

·         Route of administration

·         Dosage strength

·         Pharmacokinetics

·         Stability


The TPP is a patient and labeling centered concepts, because it identifies the desired performance characteristics of the product, related to the patient’s need and it is organized according to the key section in the drug labeling. Pharmaceutical companies will use the desired labeling information to construct a target product profile .The TPP is then used to design the clinical trials, safety and ADME studies as well as to design the drug product, i.e. The QTPP.  



QTPP is a quantitative substitute for aspects of scientific safety and efficacy that can be used to design and optimize a formulation and mfg. process. It should include quantitative targets for impurities, stability and product specific performance requirements.  QTPP is not specification because it includes tests such as bioequivalence or stability that are not carried out in batch to batch release. QTPP should only include patient relevant product performance.

The Quality Target product profile is a term that is an ordinary addition of TPP for product quality. It guides formulation scientists to establish formulation strategies and keep formulation is well-organized. QTPP is related to identity, assay, dosage form, purity, stability in the label.



A CQA has been defined as “a physical, chemical, biological or microbiological property or characteristics that should be within an appropriate limit, range, or distribution to ensure the desired product quality.” Identification of CQAs is done through risk assessment as per the ICHQ9. Critical Quality Attributes are generally associated with the drug substance, excipients, intermediates and drug product. Critical Quality attributes includes the properties that impart the desired quality, safety, and efficacy. CQAs for biotechnological products are typically those aspects affecting product purity, stability. Drug product CQAs can be identified from the Target product profile.   Use of strong risk estimation methods for identification of CQAs is new to the QbD standard.



Risk assessment is the linkages between material attributes and process parameters. It is performed during the lifecycle of the product to identify the critical material attributes and critical process parameters.



A material attributes can be an excipients raw material, drug substances, reagents, solvents, packaging and labeling materials. A material attributes can be quantified and typically fixed but sometimes can be changed during further processing.


E.g. Impurity profile, porosity, specific volume, sterility.



Process parameters variability has an impact on a critical quality attributes and therefore should be monitored and controlled to ensure the process produces the desired quality. (ICHQ8) Process parameters can be measured and controlled.


Quality Risk Assessment:

·         The evaluation of the risk to quality should be based on scientific knowledge and it provides safety to the patient.

·         Describes systematic processes for the assessment, control, communication and review of quality risks.

·         Applies over the products lifecycle, development, manufacturing and distribution.



Critical Material Attributes (CMA) and Critical Process Parameters Criticality (CPP):

·         A material attributes is critical when a practical change in that attribute can significantly impact the quality of the output material.

·         A process parameters is critical when it has a high impact on a critical quality attributes.

·         CPPs are responsible for ensuring the CQAs and it is identified from a list of potential CPPs using risk assessment..


Three categories for attributes or parameters -

·         Unclassified parameters – The criticality of unclassified parameters is undetermined or unknown. The additional data are needed to classify an unclassified parameter as critical or non – critical.

·         Critical parameters – A parameter is critical when a realistic change in that parameter can cause the product to fail to get the QTPP.

·         Non – critical parameter- No failure in QTPP observed in the potential operating space and no interactions with other parameters in the established suitable range.


Examples for CPP: Temperature, addition rate, cooling rate, rotation speed, pH, agitation, dissolved oxygen.


A Design Space:

A Design space is defined as, “Multidimensional combination and interaction of input variables (e.g. material attributes and process parameters) that have been demonstrated to provide assurance of quality.”


The linkage between the process inputs and critical quality attributes can be described in the design space. A design space is a way to represent the process understanding that has been established.


Fig 2: Design Space 


It is proposed by Applicant and reviewed by controller. In a typical design space approach a sponsor identifies the unclassified parameters and then does a DOE on some of the unclassified parameters with the other unclassified parameter. Analysis of historical data can provide the basis for establishing a design space. How a design is developed, it is expected that operation within the design space will result in a product meeting the defined quality attributes. Once design space is accepted, then regulatory post approval change requirements will be simplified inside space. When you define your design space, then you are able to plan how to control process.  


Control Strategy

Control strategy is defined as, “A designed set of control, derived from current product and process understanding that assures process performance and product quality.” A control strategy is designed to ensured that product of required quality will be produce consistently. Once sufficient level of process understanding is achieved, a control strategy should be developed that assures the process will remain in control within normal variation in material attributes and process operating ranges.


A control strategy may include input material controls, process controls, and monitoring, design spaces around individual or multiple unit operations, and final product specifications used to ensure consistent quality.



·         Procedural controls

·         In- process controls

·         batch release testing

·         Process monitoring

·         Characterization testing

·         Comparability testing

·         Constancy testing


The control strategy in the QbD standard is established via risk assessment that takes in to account the criticality of the CQAs.


IFM (Impurity Fate Mapping) - Is such an example in which raw material and process impurity sources are identify and their fate mapped throughout process. Remove impurity is an essential element of control strategy. 


Product Lifecycle Management and Continual Improvement:

Throughout the product lifecycle, companies have opportunities to evaluate modern approaches to improve product quality. After approval, CQAs would be monitored to ensure that the process is performing within the defined suitable variability that served as the basis for the filed process design space. The primary benefit of an extended process design space would be a more flexible approach by regulatory agencies. Therefore, process improvements during the product life cycle with regard to process consistency.


Application of QbD to Influenza Vaccines:

Influenza vaccine:    

Influenza (flu) is caused by influenza viruses and is spread mainly by coughing, sneezing, and close contact with infected person..


Flu is communicable disease that spreads around the US every winter in Oct.


·         Fever/chills

·         Sore throat

·         Muscle aches

·         Fatigue

·         Cough

·         Headache



Vaccination is the phenomenon of protective immunization. In modern concept vaccination involves the administration (injection or oral) of an antigen to obtain an antibody response that will protect the organism against future infections. Attenuated viruses are the genetically modified pathogenic organisms that are made non pathogenic andused as vaccines. Attenuated strains of some pathogenic organisms were prepared by prolonged cultivation for weeks, months or years. Due to this, infectious organism would lose its ability to cause disease but retains its capacity to act as an immunizing agent.   Flu vaccine is the best protection against flu and its complications. Flu vaccine is also helps to prevent spreading flu from person to persons. Flu vaccine can not prevent all cases of flu but it is the best protection against the acute respiratory diseases.


Some people should not get this vaccine-

1)       If they have any severe, life – threatening allergies. E.g – Allergy to gelatin, antibiotics or eggs, you may be not to get vaccinated.

2)       If you are not feeling well, then also not to get vaccinated.



Table No 2: Quality target product profile




of Action

Type A –VAX is a pentavalent vaccines containg the capsular polysaccharide of 5 serotypes, each linked to a recombinant non – infectious virus- like particle (VLP).Expected to produced enhanced cellular antigen specific protective immunity.


Active immunization of 2-60 month old infants and children for prevention of disease related illnesses due to causative agents.

Primary Endpoints

70% reduction of confirmed disease within 1 year after dosing in the target population, safe and tolerable.

Key Claims

Easy to administer, 0.5ml subcutaneous delivery in an outpatient setting using a 1ml syringe.

Stability-2 years at RT.


Sterile product, 3 doses administered 2 months apart.

Label volume-0.5 ml

Primary packaging: Single dose vial, clear Type 1 glass.

Secondary packaging: 10 vials/cartons.

Approvals and Recommendations

Expecting Advisory committee on Immunization practices and other universal recommendations


Cell- Culture Based Influenza Vaccine Production12:


1)       Modern cell – culture technology potentially allows for quick, efficient production.

2)       Production of cell derived vaccine requires little advanced planning and many provide response in the event of virus.

Influenza vaccine production process involves 5 fundamental steps:

1)       Cell propagation / Preparation of substrate.

2)        Virus propagation

3)        Purification

4)        Inaction and Splitting

5)        Blending, Filling, and Approval.


1)       Cell propagation / Preparation of substrate:

Take the frozen, preserved cell culture from WBC cell line and grown in an incubator at 370c. Then this cells are first grown in small volume of culture medium, due to this cells are grown and multiply. Then transfer in to succively larger container.




2)       Virus propagation:

Once a high number of cells have been produced, Add influenza seed virus obtained from WHO diagnostic laboratory in to cell containing bioreactor (Fermenter) where virus infects the cells and multiplies and produce the more virus particles. After several days viruses destroyed the cell in bioreactors. The virus is harvested by removing the waste made by the cells and made non infectious.

3)       Purification:

Using a centrifuge or chromatography, the virus is then separated from the cells and removes from the solution

4)       Inactivation and Splitting:

A chemical process is used to inactivate the virus, stripping it of its ability to infect, for that formaldehyde is used, this is called as splitting. Then the surface antigen is separated and extracted from the virus.

5)       Blending, Filling and Approval :

Non infectious solution is blended, concentrated and filled into sterile syringe.


By using QbD the following parameters should be controlled during vaccine production process…8

1)       Cell propagation: In this step, limiting concentration of nutrients may be helpful for optimal cell growth. If high nutrient concentration then it inhibit cell growth. For that to do on line monitoring of the nutrients concentration.

2)       Virus prorogation:  The following variable parameters controlled during fermentation process.

·         pH- for maximum effectiveness of fermentation can be achieved by continuous monitoring pH i.e. It required most favorable pH.

·         Temperature –Temperature control is important for good fermentation process. If temperature is lower then it causes reduced product formation and if it is higher then it affects the growth of organisms.  For avoiding this, bioreactors equipped with heating and cooling system as per the requirement to maintain the reaction vessel at optimal temperature.

·         Dissolved oxygen – Optimal supply of nutrients and oxygen, due to this it prevents the growth of toxic metabolic byproducts.

·         Agitation – Good mixing also creates a favorable environment for growth and good product formation. If agitation is excessive then it damages the cells and increase temperature of medium.

·         Foam formation- Avoiding this parameter antifoam chemicals are used such as mineral oils, vegetable oils which lowers the surface tension of the medium and causes foam bubbles to collapse. Also mechanical foam control devices fitted at top of fermenter.

3)       Purification: in this step check the purity by using ion exchange chromatography and remove the impurity.

4)       Inactivation: Optimum concentration of formaldehyde is used for inactivation of viruses.


Quality by design is an essential part of modern approach pharmaceutical quality. Identification of critical material attributes that provides a link of the product quality to the mfg. process. The role of control strategy as the mechanism for completion of QbD elements into practice. It is an efficient path to the design space through the identification of non interacting process variables. QbD also having wide scope in biotechnological products such as vaccines, enzymes, monoclonal antibody etc not only in dosage forms. Quality by Design acts as a regulatory shift, which facilitate manufacturing designs and product approvals for vaccines and other products.



1.        Gillian Doherty and Jane Beach Martha Friendlyn, “Quality by design: What do we know about quality in early learning and child care, and what do we think?” A literature review.

2.        ICH Q8 (R2) Pharmaceutical Development, November 2009

3.        Lawrence X. Yu, Director of science. “Implementation of Quality by Design”, Question based review (2006).

4.        Inna Ben Anat QbD Strategy Leader, “Bud implementation in Generic Industry: Overview and Case-Study”; IFPAC JAN 2013.

5.        John Avellant, “Why Quality by Design?” March 2008 (1- 12).

6.        Sandipan Roy, “Quality by Design-Holistic concept of concept of building quality in     pharmaceuticals”. Review article. Int. J Pham Biomed Res 2012, 3(2), 100-108.

7.        Timothy D. Blackburn, “An Introduction to QbD (Quality by Design) and Implications for Technical Professionals”, ISPE CASA Annual Technology Show: April 5, 2011.

8.        U. Satyanarayana, “A text book of Biotechnology”. Page no 513, 246.

9.        Nishendu P. Nadpara and Rakshit V. Thumar. “A complete review of Quality by Design” November 2012.

10.     Lawrence X. Yu, “Quality by Design: Concept for ANDA’s”, Received Dec.2007, Accepted Feb 2008.

11.     ICH Q9: Quality Risk Management – an update 14 May 2014, www.ich.org.

12.     Ambrozaitis, Arvydas et al. A novel mammalian cell- culture technique for consistent production of influenza virus vaccine. In Vaccine. Vol 27. Issue 43.Oct. 9, 2009: 6022-6029.

13.     A-VAX case study: Applying Quality by Design to vaccines.




Received on 19.11.2015          Accepted on 27.12.2015        

© Asian Pharma Press All Right Reserved

Asian J. Res. Pharm. Sci. 6(1): Jan.-Mar., 2016; Page 45-50

DOI: 10.5958/2231-5659.2016.00007.2